CurrentPremera BluecrossPolicy N/A

MEDICAL POLICY 7.03.15 Urinary Test for Renal Allograft Dysfunction

Policy governs coverage of urine testing for CXCL10/IP-10 chemokine to detect or monitor renal allograft dysfunction (including surveillance and suspicion of acute rejection), and provides coding, evidence summary, and regulatory/benefit application notes for Premera Bluecross.

Policy Summary

PayerPremera Bluecross

PolicyMEDICAL POLICY 7.03.15 Urinary Test for Renal Allograft Dysfunction

Policy CodePolicy N/A

Change TypeNew policyCPT code added

Effective DateOct 1, 2025

Next Review DateN/A

Key ActionDocument that urinary CXCL10 testing is considered investigational; tests may not meet medical necessity for coverage to monitor or determine need for biopsy after renal transplant.

SourceLink

POLICY UPDATE CHANGES

New policy approved September 9, 2025; effective October 1, 2025.

Inclusion of CPT code 0526U effective 01/01/25.

1Investigational stance

0526UCPT code listed

ESOT/KDIGOGuideline citations

2Ongoing trials

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy subject: Urinary CXCL10 (IP-10) test for renal allograft dysfunction. Payer: Premera Bluecross (policy document for medical coverage).

Scope summary: This policy governs coverage of urine testing for the CXCL10/IP-10 chemokine to detect or monitor renal allograft dysfunction, including surveillance and evaluation to determine need for biopsy, and provides coding, evidence summary, and regulatory/benefit application notes for Premera Bluecross.

High-level coverage stance: The measurement of urinary CXCL10 chemokines to monitor for dysfunction or determine the need for biopsy after renal transplant is considered investigational / not covered by this policy.

Policy dates: Effective date 2025-10-01; last review/approval 2025-09-09.

Key policy facts

Policy titleMEDICAL POLICY 7.03.15 Urinary Test for Renal Allograft Dysfunction

PayerPremera Bluecross

Coverage stanceInvestigational / Not Covered for monitoring or determining need for biopsy

Effective date2025-10-01

Last review2025-09-09

Listed CPT code countRelevant CPT code listed = 1

Medical-Necessity Determination

Medically Necessary / Investigational determination

Coverage position:

Medically Necessary / Investigational determination: The measurement of urinary CXCL10 chemokines to monitor for dysfunction or determine the need for biopsy after renal transplant is considered investigational.

Not Covered / Investigational

Policy conclusion (plain language): Testing urinary CXCL10 to surveil for renal allograft dysfunction or to decide whether a biopsy is needed after kidney transplant is considered investigational and is not established as a covered, medically necessary service.

Evidence gap summary: Systematic reviews, a randomized controlled trial, and multiple observational studies show an association between elevated urinary CXCL10 (and related chemokines) and alloimmune injury or infection, but no studies have demonstrated clinical validity or that use of CXCL10 testing changes management or improves patient health outcomes. In particular, there are no clinical trials in which urinary CXCL10 testing guided treatment decisions or reported resulting management changes, leaving insufficient evidence that testing improves net health outcomes.

Provider Actions & Billing Notes

Documentation Required

Investigation-only coverage stance

Document that urinary CXCL10 testing is considered investigational; tests may not meet medical necessity for coverage to monitor or determine need for biopsy after renal transplant.

Affected CPT code: 0526U

Billing Rule

Test performed only at specified lab

One Lambda CXCL10 test is performed only in the company's (One Lambda/ThermoFisher) laboratory; may require out-of-network referral per benefit application.

Affected CPT code: 0526U
Note: Test performed only in One Lambda/ThermoFisher laboratory; may require out-of-network referral

Prior Authorization

Potential out-of-network referral requirement

Monitoring kidney transplantation rejection is a specialized procedure that may require an out-of-network referral; providers should consult member benefits for referral/authorization requirements.

Consult member benefits to determine if out-of-network referral or prior authorization is required

Background & Evidence Summary

Background: Urine-based biomarkers such as the CXC chemokines CXCL9 and CXCL10 (IP-10) have been studied as noninvasive markers of renal allograft inflammation and rejection because these chemokines rise with immune-mediated injury and can be measured in urine.

Commercial assay information: One Lambda (ThermoFisher) offers a CLIA laboratory-developed CXCL10 urine assay that reports CXCL10 concentration in urine, typically as pg/mL creatinine for baseline and monitoring over time.

Evidence types and limitations: The evidence base includes systematic reviews, at least one randomized controlled trial, and multiple observational and prospective cohort studies demonstrating associations with rejection, but the literature has not yet established clinical validity or shown that testing leads to management changes or improved outcomes; therefore evidence is insufficient to support routine clinical use.

Evidence element	Summary
Evidence synthesis
Systematic review, 1 RCT, and multiple observational studies show association of urinary chemokines with alloimmune injury but insufficient evidence that testing improves net health outcomes or guides treatment decisions.

Glossary:

CXCL10/IP-10 Urine Test — A urine assay measuring the chemokine CXCL10 (also called IP-10, interferon-γ–induced protein 10), a protein involved in the kidney transplant immune response; the assay reports urine concentration (for example, expressed as pg/mL creatinine).

Revision History

2025-09-09policy_creationLatest

New policy approved September 9, 2025; policy created with literature review through July 10, 2025 and states that urinary CXCL10 measurement is investigational.

2025-10-01effective_date

Policy effective October 1, 2025.

2025-01-01coding_update

Inclusion of CPT code 0526U for quantification of CXCL10 urine (reported as pg/mL creatinine) effective 01/01/25.

Policy Summary

PayerPremera Bluecross

PolicyMEDICAL POLICY 7.03.15 Urinary Test for Renal Allograft Dysfunction

Policy CodePolicy N/A

Change TypeNew policyCPT code added

Effective DateOct 1, 2025

Next Review DateN/A

Key ActionDocument that urinary CXCL10 testing is considered investigational; tests may not meet medical necessity for coverage to monitor or determine need for biopsy after renal transplant.

SourceLink

On This Page

OpenPayer

MEDICAL POLICY 7.03.15 Urinary Test for Renal Allograft Dysfunction

Coverage Summary

Medical-Necessity Determination

Not Covered / Investigational

Coding

Provider Actions & Billing Notes

Background & Evidence Summary

Medicare Determinations

Revision History